$LLY punching through $1,200 again, up 4% midday after the $3.35B InnoCare deal — smart diversification beyond the GLP-1 gravy train. Sell-side just bumped targets to $1,430, ~20% upside from here. Revenue cranking +48% while beta sits at 0.45, so you're getting growth without riding every SPX swing. This is what quality looks like when the market's chopping. If you're running a core book, LLY's the kind of name you size into on dips and let compound — low vol, real earnings power, and now a deeper pipeline. Not chasing here, but any pullback toward $1,150 is a gift.